{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:32:19Z","timestamp":1794634339221,"version":"4.9.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK115534"],"award-info":[{"award-number":["R01DK115534"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","award":["20OK016"],"award-info":[{"award-number":["20OK016"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.diabres.2024.111745","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T09:23:22Z","timestamp":1718270602000},"page":"111745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care"],"prefix":"10.1016","volume":"213","author":[{"given":"Daniel V.","family":"O\u2019Hara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0059-872X","authenticated-orcid":false,"given":"Roemer J.","family":"Janse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9698-6825","authenticated-orcid":false,"given":"Edouard L.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg J.","family":"Jardine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Jesus","family":"Carrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.diabres.2024.111745_b0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease","volume":"12","author":"Thomas","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"13","key":"10.1016\/j.diabres.2024.111745_b0010","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1001\/archinte.164.13.1422","article-title":"The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13 000 men and women with 20 years of follow-up","volume":"164","author":"Almdal","year":"2004","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.diabres.2024.111745_b0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","article-title":"Heart failure in type 2 diabetes mellitus","volume":"124","author":"Kenny","year":"2019","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.diabres.2024.111745_b0020","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2337\/dc17-1962","article-title":"Global economic burden of diabetes in adults: projections from 2015 to 2030","volume":"41","author":"Bommer","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2024.111745_b0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2024.111745_b0030","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes. Diabetes Care. 2022;45(Suppl 1):S125-s43.","DOI":"10.2337\/dc22-S009"},{"key":"10.1016\/j.diabres.2024.111745_b0035","unstructured":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788-801."},{"issue":"10","key":"10.1016\/j.diabres.2024.111745_b0040","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.diabres.2024.111745_b0045","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.diabres.2024.111745_b0050","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.diabres.2024.111745_b0055","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.diabres.2024.111745_b0060","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2215\/CJN.02980322","article-title":"Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease","volume":"17","author":"Tuttle","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.diabres.2024.111745_b0065","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2337\/dc21-0723","article-title":"Chronic kidney disease testing among at-risk adults in the U.S. remains low: real-world evidence from a national laboratory database","volume":"44","author":"Alfego","year":"2021","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2024.111745_b0070","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dom.13160","article-title":"Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis","volume":"20","author":"McGovern","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.diabres.2024.111745_b0075","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s11606-017-4198-4","article-title":"Advancing the science and practice of medication adherence","volume":"33","author":"Stirratt","year":"2018","journal-title":"J Gen Intern Med"},{"issue":"11","key":"10.1016\/j.diabres.2024.111745_b0080","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2337\/dc16-1925","article-title":"Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis","volume":"40","author":"Khunti","year":"2017","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2024.111745_b0085","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/joim.13418","article-title":"The Stockholm CREAtinine Measurements (SCREAM) project: fostering improvements in chronic kidney disease care","volume":"291","author":"Carrero","year":"2022","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.diabres.2024.111745_b0090","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/ckj\/sfv117","article-title":"The Stockholm CREAtinine Measurements (SCREAM) project: protocol overview and regional representativeness","volume":"9","author":"Runesson","year":"2016","journal-title":"Clin Kidney J"},{"issue":"19","key":"10.1016\/j.diabres.2024.111745_b0095","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2024.111745_b0100","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter Suppl; 2013; 3:1-150."},{"issue":"9","key":"10.1016\/j.diabres.2024.111745_b0105","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1185\/03007990903126833","article-title":"Good and poor adherence: optimal cut-point for adherence measures using administrative claims data","volume":"25","author":"Karve","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabres.2024.111745_b0110","unstructured":"R Core Team. R: A language and environment for statistical computing (2021). R Foundation for Statistical Computing, Vienna, Austria. URL: https:\/\/www.R-project.org\/."},{"issue":"S138","key":"10.1016\/j.diabres.2024.111745_b0115","article-title":"PDB116 - The relationship between poor adherence and HbA1c and weight changes in patients with type 2 diabetes","volume":"21","author":"Ramos","year":"2018","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.diabres.2024.111745_b0120","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/phar.2107","article-title":"Association between medication adherence and the outcomes of heart failure","volume":"38","author":"Hood","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.diabres.2024.111745_b0125","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00228-023-03467-7","article-title":"Evidence-based medication adherence among seniors in the first year after heart failure hospitalisation and subsequent long-term outcomes: a restricted cubic spline analysis of adherence-outcome relationships","volume":"79","author":"Qin","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.diabres.2024.111745_b0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.5554","article-title":"Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and\/or ezetimibe","volume":"1","author":"Khunti","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"24","key":"10.1016\/j.diabres.2024.111745_b0135","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.diabres.2024.111745_b0140","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabres.2024.111745_b0145","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000742","article-title":"Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?","volume":"7","author":"Shao","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"5","key":"10.1016\/j.diabres.2024.111745_b0150","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s13300-018-0483-4","article-title":"Persistence to treatment with novel antidiabetic drugs (dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists) in people with type 2 diabetes: a nationwide cohort study","volume":"9","author":"Jermendy","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2024.111745_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109035","article-title":"Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting","volume":"180","author":"Rea","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"10.1016\/j.diabres.2024.111745_b0160","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1080\/03007995.2017.1320277","article-title":"Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States","volume":"33","author":"Cai","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.diabres.2024.111745_b0165","doi-asserted-by":"crossref","first-page":"e014287","DOI":"10.1136\/bmjopen-2016-014287","article-title":"Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries","volume":"7","author":"Morgan","year":"2017","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.diabres.2024.111745_b0170","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3121\/cmr.2013.1113","article-title":"Patient characteristics associated with medication adherence","volume":"11","author":"Rolnick","year":"2013","journal-title":"Clin Med Res"},{"issue":"2","key":"10.1016\/j.diabres.2024.111745_b0175","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/dom.13531","article-title":"Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors","volume":"21","author":"Dave","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.diabres.2024.111745_b0180","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1185\/03007995.2013.821056","article-title":"Predictors of medication adherence in patients with type 2 diabetes mellitus","volume":"29","author":"Curkendall","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.diabres.2024.111745_b0185","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.diabet.2012.12.005","article-title":"Difficulty adhering to antidiabetic treatment: factors associated with persistence and compliance","volume":"39","author":"Gu\u00e9nette","year":"2013","journal-title":"Diabetes Metab"},{"issue":"3","key":"10.1016\/j.diabres.2024.111745_b0190","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40618-019-01110-w","article-title":"Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study","volume":"43","author":"Fadini","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"10.1016\/j.diabres.2024.111745_b0195","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2337\/dc14-2098","article-title":"Determinants of adherence to diabetes medications: findings from a large pharmacy claims database","volume":"38","author":"Kirkman","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2024.111745_b0200","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.diabres.2024.111745_b0205","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/MLR.0b013e31819a5acc","article-title":"Physician communication and patient adherence to treatment: a meta-analysis","volume":"47","author":"Zolnierek","year":"2009","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.diabres.2024.111745_b0210","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00592-020-01590-w","article-title":"Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes","volume":"58","author":"Ogundipe","year":"2021","journal-title":"Acta Diabetol"},{"issue":"1","key":"10.1016\/j.diabres.2024.111745_b0215","doi-asserted-by":"crossref","first-page":"e3350","DOI":"10.1002\/dmrr.3350","article-title":"Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: Evidence from a systematic review and meta-analysis","volume":"37","author":"Ofori-Asenso","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabres.2024.111745_b0220","doi-asserted-by":"crossref","unstructured":"Williams S, Ahmed S. 1224-P: Improving compliance with SGLT2 inhibitors by reducing the risk of genital mycotic infections: the outcomes of personal hygiene advice. Diabetes. 2019;68(Supplement_1).","DOI":"10.2337\/db19-1224-P"},{"issue":"2","key":"10.1016\/j.diabres.2024.111745_b0225","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2337\/ds20-0025","article-title":"Exploring why people with type 2 diabetes do or do not persist with glucagon-like peptide-1 receptor agonist therapy: a qualitative study","volume":"34","author":"Polonsky","year":"2021","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.diabres.2024.111745_b0230","article-title":"Incidence and predictors of primary nonadherence to sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 agonists in a large integrated healthcare system","author":"Luo","year":"2022","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.diabres.2024.111745_b0235","unstructured":"Swedish National Board of Health and Welfare. Statistical Database, Pharmaceuticals. Stockholm: Swedish National Board of Health and Welfare; 2019 Apr 23 [updated 2024 Mar 27; cited 2024 Apr 15]. Available from: https:\/\/sdb.socialstyrelsen.se\/if_lak\/val_eng.aspx."},{"key":"10.1016\/j.diabres.2024.111745_b0240","doi-asserted-by":"crossref","unstructured":"Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487-93.","DOI":"10.2337\/dci19-0066"},{"key":"10.1016\/j.diabres.2024.111745_b0245","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142021. Diabetes Care. 2020;44(Supplement_1):S111-S24.","DOI":"10.2337\/dc21-S009"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724006557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724006557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:46:57Z","timestamp":1770050817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822724006557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":49,"alternative-id":["S0168822724006557"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111745","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111745","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111745"}}